For research use only. Not for therapeutic Use.
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1].
SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1].
SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1].
Catalog Number | I044450 |
CAS Number | 1282606-48-7 |
Synonyms | 3-[1-[(4-fluorophenyl)methyl]-5-oxo-1,2,4-triazol-4-yl]-N-(pyridin-3-ylmethyl)-1H-pyrazole-5-carboxamide |
Molecular Formula | C19H16FN7O2 |
Purity | ≥95% |
InChI | InChI=1S/C19H16FN7O2/c20-15-5-3-13(4-6-15)11-27-19(29)26(12-23-27)17-8-16(24-25-17)18(28)22-10-14-2-1-7-21-9-14/h1-9,12H,10-11H2,(H,22,28)(H,24,25) |
InChIKey | FAIXKYSRYKWWGK-UHFFFAOYSA-N |
SMILES | C1=CC(=CN=C1)CNC(=O)C2=CC(=NN2)N3C=NN(C3=O)CC4=CC=C(C=C4)F |
Reference | [1]. Sun S, et al. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors. Bioorg Med Chem. 2015;23(3):455-465. |